FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3160333863> ?p ?o ?g. }

• W3160333863 endingPage "2466" @default.
• W3160333863 startingPage "2456" @default.
• W3160333863 abstract "Abstract Next-generation sequencing (NGS) has been applied to measurable/minimal residual disease (MRD) monitoring after induction chemotherapy in patients with acute myeloid leukemia (AML), but the optimal time point for the test remains unclear. In this study, we aimed to investigate the clinical significance of NGS MRD at 2 different time points. We performed targeted NGS of 54 genes in bone marrow cells serially obtained at diagnosis, first complete remission (first time point), and after the first consolidation chemotherapy (second time point) from 335 de novo AML patients. Excluding DNMT3A, TET2, and ASXL1 mutations, which are commonly present in individuals with clonal hematopoiesis of indeterminate potential, MRD could be detected in 46.4% of patients at the first time point (MRD1st), and 28.9% at the second time point (MRD2nd). The patients with detectable NGS MRD at either time point had a significantly higher cumulative incidence of relapse and shorter relapse-free survival and overall survival. In multivariate analysis, MRD1st and MRD2nd were both independent poor prognostic factors. However, the patients with positive MRD1st but negative MRD2nd had a similar good prognosis as those with negative MRD at both time points. The incorporation of multiparameter flow cytometry and NGS MRD revealed that the presence of NGS MRD predicted poorer prognosis among the patients without detectable MRD by multiparameter flow cytometry at the second time point but not the first time point. In conclusion, the presence of NGS MRD, especially after the first consolidation therapy, can help predict the clinical outcome of AML patients." @default.
• W3160333863 created "2021-05-24" @default.
• W3160333863 creator A5002091044 @default.
• W3160333863 creator A5004007765 @default.
• W3160333863 creator A5007182076 @default.
• W3160333863 creator A5016641339 @default.
• W3160333863 creator A5020382277 @default.
• W3160333863 creator A5040824187 @default.
• W3160333863 creator A5049559598 @default.
• W3160333863 creator A5054453758 @default.
• W3160333863 creator A5055054213 @default.
• W3160333863 creator A5057809696 @default.
• W3160333863 creator A5062858623 @default.
• W3160333863 creator A5071037877 @default.
• W3160333863 creator A5073227099 @default.
• W3160333863 creator A5074799366 @default.
• W3160333863 creator A5077634268 @default.
• W3160333863 creator A5080199901 @default.
• W3160333863 creator A5087038882 @default.
• W3160333863 creator A5091017992 @default.
• W3160333863 date "2021-05-17" @default.
• W3160333863 modified "2023-10-17" @default.
• W3160333863 title "Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML" @default.
• W3160333863 cites W1920829940 @default.
• W3160333863 cites W1981449355 @default.
• W3160333863 cites W1990211056 @default.
• W3160333863 cites W1992453745 @default.
• W3160333863 cites W2071206691 @default.
• W3160333863 cites W2080104001 @default.
• W3160333863 cites W2105608321 @default.
• W3160333863 cites W2114586150 @default.
• W3160333863 cites W2144395887 @default.
• W3160333863 cites W2153994826 @default.
• W3160333863 cites W2157460080 @default.
• W3160333863 cites W2159875685 @default.
• W3160333863 cites W2169046713 @default.
• W3160333863 cites W2276580523 @default.
• W3160333863 cites W2301134026 @default.
• W3160333863 cites W2339658711 @default.
• W3160333863 cites W2419140434 @default.
• W3160333863 cites W2535248475 @default.
• W3160333863 cites W2559537906 @default.
• W3160333863 cites W2604474002 @default.
• W3160333863 cites W2738685991 @default.
• W3160333863 cites W2779613298 @default.
• W3160333863 cites W2783450169 @default.
• W3160333863 cites W2794480810 @default.
• W3160333863 cites W2799371335 @default.
• W3160333863 cites W2808117687 @default.
• W3160333863 cites W2889920057 @default.
• W3160333863 cites W2896822607 @default.
• W3160333863 cites W2896930435 @default.
• W3160333863 cites W2975689185 @default.
• W3160333863 doi "https://doi.org/10.1182/bloodadvances.2020003738" @default.
• W3160333863 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8152512" @default.
• W3160333863 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33999144" @default.
• W3160333863 hasPublicationYear "2021" @default.
• W3160333863 type Work @default.
• W3160333863 sameAs 3160333863 @default.
• W3160333863 citedByCount "26" @default.
• W3160333863 countsByYear W31603338632021 @default.
• W3160333863 countsByYear W31603338632022 @default.
• W3160333863 countsByYear W31603338632023 @default.
• W3160333863 crossrefType "journal-article" @default.
• W3160333863 hasAuthorship W3160333863A5002091044 @default.
• W3160333863 hasAuthorship W3160333863A5004007765 @default.
• W3160333863 hasAuthorship W3160333863A5007182076 @default.
• W3160333863 hasAuthorship W3160333863A5016641339 @default.
• W3160333863 hasAuthorship W3160333863A5020382277 @default.
• W3160333863 hasAuthorship W3160333863A5040824187 @default.
• W3160333863 hasAuthorship W3160333863A5049559598 @default.
• W3160333863 hasAuthorship W3160333863A5054453758 @default.
• W3160333863 hasAuthorship W3160333863A5055054213 @default.
• W3160333863 hasAuthorship W3160333863A5057809696 @default.
• W3160333863 hasAuthorship W3160333863A5062858623 @default.
• W3160333863 hasAuthorship W3160333863A5071037877 @default.
• W3160333863 hasAuthorship W3160333863A5073227099 @default.
• W3160333863 hasAuthorship W3160333863A5074799366 @default.
• W3160333863 hasAuthorship W3160333863A5077634268 @default.
• W3160333863 hasAuthorship W3160333863A5080199901 @default.
• W3160333863 hasAuthorship W3160333863A5087038882 @default.
• W3160333863 hasAuthorship W3160333863A5091017992 @default.
• W3160333863 hasBestOaLocation W31603338631 @default.
• W3160333863 hasConcept C104317684 @default.
• W3160333863 hasConcept C126322002 @default.
• W3160333863 hasConcept C143998085 @default.
• W3160333863 hasConcept C203014093 @default.
• W3160333863 hasConcept C2483381 @default.
• W3160333863 hasConcept C2776694085 @default.
• W3160333863 hasConcept C2778461978 @default.
• W3160333863 hasConcept C2778729363 @default.
• W3160333863 hasConcept C2779823535 @default.
• W3160333863 hasConcept C2911091166 @default.
• W3160333863 hasConcept C30481170 @default.
• W3160333863 hasConcept C38180746 @default.
• W3160333863 hasConcept C53226629 @default.
• W3160333863 hasConcept C54355233 @default.
• W3160333863 hasConcept C553184892 @default.

• next